NMEs On The Rebound? Pace of 2006 Novel Drug Approvals Bests 2005
New molecular entity and novel biologic approvals appear to be rebounding from 2005's low point, an analysis of CDER approvals in 2006 to date suggests
New molecular entity and novel biologic approvals appear to be rebounding from 2005's low point, an analysis of CDER approvals in 2006 to date suggests